107859-98-3

Basic information

• Product Name: 3-(4-HYDROXYMETHYL-PHENYL)-PROPIONIC ACID ETHYL ESTER
• Synonyms: 3-(4-HYDROXYMETHYL-PHENYL)-PROPIONIC ACID ETHYL ESTER;Ethyl 3-[4-(hydroxymethyl)phenyl]propanoate;Ethyl 3-(4-(hydroxymethyl)
• CAS NO: 107859-98-3
• Molecular Formula: C₁₂H₁₆O₃
• Molecular Weight: 208.25364
• Mol File: 107859-98-3.mol

Chemical Properties

• Boiling Point: 155-163 °C(Press: 0.5 Torr)
• Appearance: /
• Density: 1.101±0.06 g/cm3(Predicted)
• Storage Temp.: Sealed in dry,Room Temperature
• PKA: 14.43±0.10(Predicted)
• CAS DataBase Reference: 3-(4-HYDROXYMETHYL-PHENYL)-PROPIONIC ACID ETHYL ESTER(CAS DataBase Reference)
• NIST Chemistry Reference: 3-(4-HYDROXYMETHYL-PHENYL)-PROPIONIC ACID ETHYL ESTER(107859-98-3)
• EPA Substance Registry System: 3-(4-HYDROXYMETHYL-PHENYL)-PROPIONIC ACID ETHYL ESTER(107859-98-3)

Safety Data

• Hazardous Substances Data: 107859-98-3(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
3-(4-Hydroxymethyl-phenyl)-propionic acid ethyl ester is used as an analgesic for the management of pain, particularly in conditions characterized by inflammation. Its ability to reduce prostaglandin levels makes it effective in alleviating discomfort associated with various inflammatory disorders.
Used in Anti-inflammatory Applications:
In the medical field, this compound serves as an anti-inflammatory agent, targeting the reduction of inflammation in conditions such as arthritis and other inflammatory disorders. Its pharmacological action helps in mitigating the symptoms and progression of these diseases.
Used in Pain Management:
3-(4-Hydroxymethyl-phenyl)-propionic acid ethyl ester is utilized for pain management, especially in cases of menstrual pain and other types of acute or chronic pain that benefit from prostaglandin inhibition. Its improved bioavailability ensures more efficient pain relief.

Upstream product

• 864653-88-3 3-(4-hydroxymethylphenyl)acrylic acid ethyl ester 
• 7560-50-1 methyl (2E)-3-(4-formylphenyl)acrylate 
• 51828-89-8 ethyl 4-formylcinnamate 
• 1122-91-4 4-bromo-benzaldehyde 
• 140-88-5 ethyl acrylate 
• 3054-95-3 acrylaldehyde diethyl acetal 
• 445483-72-7 3-(4-formyl-phenyl)-propionic acid ethyl ester 

Downstream Products

• 56703-35-6 ethyl 3-[4-(bromomethyl)phenyl]propanoate 
• 878478-66-1 Ethyl 3-{4-[(methoxymethoxy)methyl]phenyl}propanoate 
• 107859-99-4 3-(4-chloromethylphenyl)propionic acid ethyl ester 

Relevant articles and documents

PYRIDINE COMPOUND SUBSTITUTED WITH AZOLE

The present invention provides a compound represented by formula [I] shown below or a pharmaceutically acceptable salt thereof that has an inhibitory effect on 20-HETE producing enzyme. (in formula [I] above, the structure represented by formula [II] below: represents any of the structures represented by formula group [III] below: R1, R2, R3, and R4 independently represent a hydrogen atom, a fluorine atom, methyl, or the like, R5 represents any of the structures represented by formula group [IV]:

GPR40 AGONISTS IN ANTI-DIABETIC DRUG COMBINATIONS

Disclosed are compositions comprising (a) a GPR40 agonist and (b) an SGLT2 inhibitor, and methods for treating of disorders that are affected by the modulation of the GPR40 receptor and SGLT2 transporter. Such GPR40 compounds are represented by Formula (I) as follows: wherein ring W, R1, R2, R3, R5, R6, A, and Z, are defined herein.

SUBSTITUTED BENZOTHIOPHENYL DERIVATIVES AS GPR40 AGONISTS FOR THE TREATMENT OF TYPE II DIABETES

Disclosed are compounds, compositions and methods for treating of disorders that are affected by the modulation of the GPR40 receptor. Such compounds are represented by Formula (I) wherein R1, R2, R3, R5, R6, W, and A are defined herein.

Design, Synthesis, and Biological Evaluation of First-in-Class Dual Acting Histone Deacetylases (HDACs) and Phosphodiesterase 5 (PDE5) Inhibitors for the Treatment of Alzheimer's Disease

Simultaneous inhibition of phosphodiesterase 5 (PDE5) and histone deacetylases (HDAC) has recently been validated as a potentially novel therapeutic approach for Alzheimer's disease (AD). To further extend this concept, we designed and synthesized the first chemical series of dual acting PDE5 and HDAC inhibitors, and we validated this systems therapeutics approach. Following the implementation of structure- and knowledge-based approaches, initial hits were designed and were shown to validate our hypothesis of dual in vitro inhibition. Then, an optimization strategy was pursued to obtain a proper tool compound for in vivo testing in AD models. Initial hits were translated into molecules with adequate cellular functional responses (histone acetylation and cAMP/cGMP response element-binding (CREB) phosphorylation in the nanomolar range), an acceptable therapeutic window (>1 log unit), and the ability to cross the blood-brain barrier, leading to the identification of 7 as a candidate for in vivo proof-of-concept testing (Cuadrado-Tejedor, M.; Garcia-Barroso, C.; Sánchez-Arias, J. A.; Rabal, O.; Mederos, S.; Ugarte, A.; Franco, R.; Segura, V.; Perea, G.; Oyarzabal, J.; Garcia-Osta, A. Neuropsychopharmacology 2016, in press, doi: 10.1038/npp.2016.163).

NOVEL COMPOUNDS AS DUAL INHIBITORS OF PHOSPHODIESTERASES AND HISTONE DEACETYLASES

It relates to certain compounds having a polycyclic structure and a hydroxamic acid moiety, wherein the polycyclic structure comprises at least three ring systems, wherein one ring system is a polycyclic ring system comprising from 2 to 4 rings; at least one ring is an aromatic ring; and wherein the structure comprises at least 3 nitrogen atoms and 1 oxygen atom. It also relates to a process for their preparation, as well as to pharmaceutical compositions containing them, and to their use in medicine, in particular in the treatment and/or prevention of neurological disorders coursing with a cognition deficit or impairment, or neurodegenerative diseases. wherein B1 is a radical selected from the group consisting of formula (A"), formula (B"), formula (C"), and formula (D"):

TROPAN COMPOUND

The conventional anticholinergic drugs for administration through inhalation have been considered to have the possibility of aggravating dysuria associated with prostatic hyperplasia mediated by blood, and it has been demanded that the conventional anticholinergic drugs for administration through inhalation will have to show reduced side effects or adverse ractions. The present invention relates to a compound represented by the general formula (I): (wherein A represents; and R1, R2, R3 and R1 each a hydrogen atom or a substituent; R5 is a substituent; X- is an anion;the symbol: denotes an exo-form or endo-form, or their mixture), its salt or solvation product thereof. They are useful as a prophylactic and/or therapeutic agent with reduced side effects or adverse reactions for the diseases mediated by the muscarinic receptor.

ALPHA-4 INTEGRIN MEDIATED CELL ADHESION INHIBITORS FOR THE TREATMENT OR PREVENTION OF INFLAMMATORY DISEASES

The present invention relates to novel compounds of formula (I), processes for their preparation, compositions comprising them and their use in the treatment or prevention of diseases capable of being modulated by the inhibition of cell adhesion.

NOVEL COMPOUNDS

The present invention relates to novel pyridone derivatives capable of inhibiting a4 integrin medicated cell adhesion, processes for their preparation, compositions comprising them and their use in the treatment of diseases capable of being modulated by t

NOVEL BENSOPHENONE DERIVATIVES OR SALTS THEREOF

A benzophenone derivative represented by the following formula: whereinR1 represents, for example, an optionally substituted heterocyclic group, or a substituted phenyl group; Z represents, for example, an alkylene group; R2 represents, for example, a carboxyl group optionally protected with alkyl;R3 represents, for example, an optionally protected hydroxyl group; R4 represents, for example, an optionally substituted cycloalkyloxy group; and R5 represents, for example, a hydrogen atom, ???or a salt thereof has anti-arthritic activity, inhibits bone destruction caused by arthritis, and provides high safety and excellent pharmacokinetics and thus is useful as therapeutic agent for arthritis. These compounds have inhibitory effect on AP-1 activity and are useful as preventive or therapeutic agent for diseases in which excessive expression of AP-1 is involved.

Thiadizazole compounds as antagonists of SRS-A

This invention relates to novel heterocyclic compounds structurally characterized by containing a specific heterocyclic group and by the presence of --CH2 --S-- directly bound to the specific heterocyclic group. These heterocyclic compounds are useful as medicines, particularly as antagonists of SRS-A (slow reacting substance of anaphylaxis).